Measuring folate receptor alpha in stored tumor samples from high-grade serous ovarian cancer
Checks folate receptor alpha levels in stored tumor tissue from women with ovarian cancer.
Plain-language title generated from the registry record
Registry title: Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
Key facts
- Where
- Athens, GreeceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older with high-grade serous epithelial ovarian cancer. It studies stored tumor samples taken at diagnosis.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- High-grade serous epithelial ovarian cancer, as stated in the pathologist's report
- Biomarker or test result
- Folate Receptor Alpha (FRα) is measured on stored tumor samples; no result is needed to join
Main reasons for not taking part
- Non-epithelial ovarian tumors
- Endometrioid, mucinous or clear cell carcinomas
- Tissue samples of poor or inadequate quality
Read by machine on 12 November 2026.
Where in Greece
- Hellenic Cooperative Oncology GroupAthens, GreeceContact: Hellenic Cooperative Oncology Group Hellenic Cooperative Oncology GroupTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hellenic Cooperative Oncology Group
- Trial code
- NCT07889843
- Record updated
- 22 October 2026
- Original description
This is a single-country, retrospective, observational biomarker study conducted in Greece to evaluate Folate Receptor Alpha (FRα) expression in patients with high-grade serous ovarian, fallopian tube, and primary peritoneal cancer at the time of diagnosis. Approximately 200 eligible female patients (≥18 years) diagnosed between 1 January 2001 and 30 July 2025 will be included from around 15 clinical sites affiliated with the Hellenic Cooperative Oncology Group.Read full original descriptionShow less
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
This is a single-country, retrospective, observational biomarker study conducted in Greece to evaluate Folate Receptor Alpha (FRα) expression in patients with high-grade serous ovarian, fallopian tube, and primary peritoneal cancer at the time of diagnosis. Approximately 200 eligible female patients (≥18 years) diagnosed between 1 January 2001 and 30 July 2025 will be included from around 15 clinical sites affiliated with the Hellenic Cooperative Oncology Group.
Historically collected Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples stored in the Hellenic Cooperative Oncology Group biobank will be analyzed centrally using the Ventana FOLR1 RxDx assay to determine FRα expression. Only samples collected at initial diagnosis will be included; relapse samples will be excluded.
The primary objective is to assess the prevalence of FRα-positive status, defined as ≥75% viable tumor cells with moderate (2+) and/or strong (3+) membrane staining. Secondary objectives include evaluation of intra-tumoral heterogeneity, concordance between primary and metastatic lesions, prevalence of lower FRα expression levels, and associations between FRα expression and clinical characteristics, BRCA/HRD status, progression-free survival (PFS), and overall survival (OS).
All analyses will be descriptive, with additional exploratory statistical methods including chi-square tests, Cohen's kappa, correlation analyses, ANOVA, Kaplan-Meier survival analysis, and Cox proportional hazards models. Data will be retrospectively collected from the Hellenic Cooperative Oncology Group registry and medical records and entered into a secure REDCap eCRF system.
Inclusion: Female patients; 18 years of age or older; Patients diagnosed with high-grade serous epithelial ovarian cancer according to pathologists' report.
Exclusion: Diagnosis of non-epithelial ovarian tumors; Diagnosis of endometrioid, mucinous, or clear cell carcinomas; Inadequate (poor quality or inadequate posology for analysis) tissue samples.